Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

@article{Gali2015InitialUO,
  title={Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.},
  author={Nazzareno Gali{\`e} and Joan Albert Barber{\`a} and Adaani E. Frost and Hossein Ardeschir Ghofrani and Marius M. Hoeper and Vallerie V McLaughlin and Andrew J. Peacock and G{\'e}rald Simonneau and J-L. Vachiéry and Ekkehard Gr{\"u}nig and Ronald J. Oudiz and Anton Vonk-Noordegraaf and R. James White and Christiana Blair and Hunter Campbell Gillies and Karen L. Miller and Julia H N Harris and Jonathan Langley and Lewis J. Rubin},
  journal={The New England journal of medicine},
  year={2015},
  volume={373 9},
  pages={
          834-44
        }
}
BACKGROUND Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg… 

Tables from this paper

Initial combination therapy with macitentan and tadalafil in pulmonary arterial hypertension: a retrospective cohort study

In a real-world setting, macitentan and tadalafil as initial combination therapy for PAH was well tolerated and yielded clinical benefit.

Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study)

Initial combination therapy with ambrisentan and tadalafil (upfront therapy) offers clinical benefits and significant haemodynamic improvement in newly diagnosed PAH patients.

Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.

Besides demographic factors, the absence of comorbidities and less severe disease state, and the use of aldosterone antagonist therapy identified patients with PAH most likely to respond to initial combination therapy with ambrisentan and tadalafil.

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

Treatment benefit from initial combination therapy appeared at least as great for FC II as for FC III participants, and the present data support an initial combination strategy for newly diagnosed patients even when symptoms are less severe.

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

The benefit of COMB over MONO was demonstrated in patients with CTD-PAH, particularly in those with typical PAH haemodynamic characteristics at baseline, and COMB is appropriate for patients categorised as low risk and intermediate risk at baseline and low risk at follow-up.

Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

Clinical benefits, including a lower risk of clinical failure, were greater with initial combination treatment with ambrisentan + tadalafil than with initial monotherapy with either ambrisentsentan or tadalafils in patients with PAH, including those in various patient subgroups.

Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU

Clinical trials have shown that ambrisentan monotherapy provides sustained clinical benefits in patients with idiopathic PAH and PAH associated with connective tissue diseases (CTD-PAH), including improvements in exercise capacity, and that initial combination treatment with ambrisENTan + tadalafil provides greater clinical benefits, including a reduced risk of clinical failure.

Hypertension: Initial combination therapy improves PAH

  • K. Huynh
  • Medicine, Psychology
    Nature Reviews Cardiology
  • 2015
The AMBITION trial supports the rationale for targeting multiple pathways in pulmonary arterial hypertension and showed that early combination therapy can be beneficial, and initial oral double combination therapy has now been included in the Joint 2015 ESC and the European Respiratory Society Guidelines.

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

Oral treprostinil–assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from Study Weeks 12–60, and the most common adverse events were headache, diarrhea, flushing, nausea, and vomiting.
...

References

SHOWING 1-10 OF 29 REFERENCES

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

Improvements in time to clinical worsening, World Health Organization functional class, Short Form-36 Health Survey score, Borg dyspnea score, and B-type natriuretic peptide were observed and ambrisentan improves exercise capacity in patients with pulmonary arterial hypertension.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

The current study failed to show a positive effect of adding inhaled iloprost to bosentan in idiopathic pulmonary arterial hypertension patients, and further studies involving larger sample sizes and long-term follow-up are needed to determine the efficacy.

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.

  • K. KempL. Savale O. Sitbon
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2012

Tadalafil Therapy for Pulmonary Arterial Hypertension

In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.

Riociguat for the treatment of pulmonary arterial hypertension.

Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension and showed significant improvements in pulmonary vascular resistance, NT-proBNP levels, World Health Organization functional class, and time to clinical worsening.

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2

This study showed a trend but no statistical significance towards haemodynamics or clinical improvement due to the combination of bosentan and epoprostenol therapy in patients with pulmonary arterial hypertension.

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

Results of this study demonstrate that the addition of inhaled iloprost in patients with PAH with reduced exercise capacity on bosentan monotherapy is safe and efficacious.